These results not only suggest that FAM110B may be an effective prognostic biomarker closely associated with tumor immunomodulatory mechanisms and anti-tumor drug resistance, but also reveal its role as a potential predictor of pan-cancer immunotherapy. The gene discussed is FAM110B; the disease is neoplasm.